Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y)

Keun Wook Lee; Dae Young Zang; Hyung Don Kim; Jin Won Kim; Bum Jun Kim; Yoon Koo Kang; Min Hee Ryu; Hark Kyun Kim

doi:10.1038/s41416-025-03267-z

Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y)

Keun Wook Lee
, Dae Young Zang
, Hyung Don Kim
, Jin Won Kim
, Bum Jun Kim
, Yoon Koo Kang
, Min Hee Ryu
, Hark Kyun Kim

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Correction to: British Journal of Cancerhttps://doi.org/10.1038/s41416-025-03052-y, published online 21 May 2025 In this article the author’s name Dae Young Zang was incorrectly written as Da Young Zang. The original article has been corrected.

Original language	English (US)
Pages (from-to)	1928
Number of pages	1
Journal	British journal of cancer
Volume	133
Issue number	12
DOIs	https://doi.org/10.1038/s41416-025-03267-z
State	Published - Dec 28 2025
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/s41416-025-03267-z

Fingerprint

Dive into the research topics of 'Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y)'. Together they form a unique fingerprint.

Cite this

Lee, K. W., Zang, D. Y., Kim, H. D., Kim, J. W., Kim, B. J., Kang, Y. K., Ryu, M. H., & Kim, H. K. (2025). Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y). British journal of cancer, 133(12), 1928. https://doi.org/10.1038/s41416-025-03267-z

Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y). / Lee, Keun Wook; Zang, Dae Young; Kim, Hyung Don et al.
In: British journal of cancer, Vol. 133, No. 12, 28.12.2025, p. 1928.

Research output: Contribution to journal › Comment/debate › peer-review

Lee, KW, Zang, DY, Kim, HD, Kim, JW, Kim, BJ, Kang, YK, Ryu, MH & Kim, HK 2025, 'Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y)', British journal of cancer, vol. 133, no. 12, pp. 1928. https://doi.org/10.1038/s41416-025-03267-z

Lee KW, Zang DY, Kim HD, Kim JW, Kim BJ, Kang YK et al. Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y). British journal of cancer. 2025 Dec 28;133(12):1928. doi: 10.1038/s41416-025-03267-z

Lee, Keun Wook ; Zang, Dae Young ; Kim, Hyung Don et al. / Correction to : Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y). In: British journal of cancer. 2025 ; Vol. 133, No. 12. pp. 1928.

@article{ac046cad3df4405a9063cf136350c841,

title = "Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y)",

abstract = "Correction to: British Journal of Cancerhttps://doi.org/10.1038/s41416-025-03052-y, published online 21 May 2025 In this article the author{\textquoteright}s name Dae Young Zang was incorrectly written as Da Young Zang. The original article has been corrected.",

author = "Lee, \{Keun Wook\} and Zang, \{Dae Young\} and Kim, \{Hyung Don\} and Kim, \{Jin Won\} and Kim, \{Bum Jun\} and Kang, \{Yoon Koo\} and Ryu, \{Min Hee\} and Kim, \{Hark Kyun\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2025.",

year = "2025",

month = dec,

day = "28",

doi = "10.1038/s41416-025-03267-z",

language = "English (US)",

volume = "133",

pages = "1928",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Correction to

T2 - Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y)

AU - Lee, Keun Wook

AU - Zang, Dae Young

AU - Kim, Hyung Don

AU - Kim, Jin Won

AU - Kim, Bum Jun

AU - Kang, Yoon Koo

AU - Ryu, Min Hee

AU - Kim, Hark Kyun

PY - 2025/12/28

Y1 - 2025/12/28

N2 - Correction to: British Journal of Cancerhttps://doi.org/10.1038/s41416-025-03052-y, published online 21 May 2025 In this article the author’s name Dae Young Zang was incorrectly written as Da Young Zang. The original article has been corrected.

AB - Correction to: British Journal of Cancerhttps://doi.org/10.1038/s41416-025-03052-y, published online 21 May 2025 In this article the author’s name Dae Young Zang was incorrectly written as Da Young Zang. The original article has been corrected.

UR - https://www.scopus.com/pages/publications/105021442056

UR - https://www.scopus.com/pages/publications/105021442056#tab=citedBy

U2 - 10.1038/s41416-025-03267-z

DO - 10.1038/s41416-025-03267-z

M3 - Comment/debate

C2 - 41219392

AN - SCOPUS:105021442056

SN - 0007-0920

VL - 133

SP - 1928

JO - British journal of cancer

JF - British journal of cancer

IS - 12

ER -

Correction to: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer (British Journal of Cancer, (2025), 133, 2, (208-215), 10.1038/s41416-025-03052-y)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this